Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy

Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through association with haptoglobin-related protein. APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-Americ...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 100; no. 10; pp. 1275 - 1284
Main Authors Saraf, S. L., Zhang, X., Shah, B., Kanias, T., Gudehithlu, K. P., Kittles, R., Machado, R. F., Arruda, J. A. L., Gladwin, M. T., Singh, A. K., Gordeuk, V. R.
Format Journal Article
LanguageEnglish
Published Italy Ferrata Storti Foundation 01.10.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through association with haptoglobin-related protein. APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-American population. A single report associated APOL1 G1/G2 with sickle cell nephropathy. In 221 patients with sickle cell disease at the University of Illinois at Chicago, we replicated the finding of an association of APOL1 G1/G2 with proteinuria, specifically with urine albumin concentration (β=1.1, P=0.003), observed an even stronger association with hemoglobinuria (OR=2.5, P=4.3×10(-6)), and also replicated the finding of an association with hemoglobinuria in 487 patients from the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy study (OR=2.6, P=0.003). In 25 University of Illinois sickle cell disease patients, concentrations of urine kidney injury molecule-1 correlated with urine cell-free hemoglobin concentrations (r=0.59, P=0.002). Exposing human proximal tubular cells to increasing cell-free hemoglobin led to increasing concentrations of supernatant kidney injury molecule-1 (P=0.01), reduced viability (P=0.01) and induction of HMOX1 and SOD2. HMOX1 rs743811 associated with chronic kidney disease stage (OR=3.0, P=0.0001) in the University of Illinois cohort and end-stage renal disease (OR=10.0, P=0.0003) in the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy cohort. Longer HMOX1 GT-tandem repeats (>25) were associated with lower estimated glomerular filtration rate in the University of Illinois cohort (P=0.01). Our findings point to an association of APOL1 G1/G2 with kidney disease in sickle cell disease, possibly through increased risk of hemoglobinuria, and associations of HMOX1 variants with kidney disease, possibly through reduced protection of the kidney from hemoglobin-mediated toxicity.
AbstractList Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through association with haptoglobin-related protein. APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-American population. A single report associated APOL1 G1/G2 with sickle cell nephropathy. In 221 patients with sickle cell disease at the University of Illinois at Chicago, we replicated the finding of an association of APOL1 G1/G2 with proteinuria, specifically with urine albumin concentration (β=1.1, P=0.003), observed an even stronger association with hemoglobinuria (OR=2.5, P=4.3×10(-6)), and also replicated the finding of an association with hemoglobinuria in 487 patients from the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy study (OR=2.6, P=0.003). In 25 University of Illinois sickle cell disease patients, concentrations of urine kidney injury molecule-1 correlated with urine cell-free hemoglobin concentrations (r=0.59, P=0.002). Exposing human proximal tubular cells to increasing cell-free hemoglobin led to increasing concentrations of supernatant kidney injury molecule-1 (P=0.01), reduced viability (P=0.01) and induction of HMOX1 and SOD2. HMOX1 rs743811 associated with chronic kidney disease stage (OR=3.0, P=0.0001) in the University of Illinois cohort and end-stage renal disease (OR=10.0, P=0.0003) in the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy cohort. Longer HMOX1 GT-tandem repeats (>25) were associated with lower estimated glomerular filtration rate in the University of Illinois cohort (P=0.01). Our findings point to an association of APOL1 G1/G2 with kidney disease in sickle cell disease, possibly through increased risk of hemoglobinuria, and associations of HMOX1 variants with kidney disease, possibly through reduced protection of the kidney from hemoglobin-mediated toxicity.
Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through association with haptoglobin-related protein. APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-American population. A single report associated APOL1 G1/G2 with sickle cell nephropathy. In 221 patients with sickle cell disease at the University of Illinois at Chicago, we replicated the finding of an association of APOL1 G1/G2 with proteinuria, specifically with urine albumin concentration (β=1.1, P=0.003), observed an even stronger association with hemoglobinuria (OR=2.5, P=4.3×10−6), and also replicated the finding of an association with hemoglobinuria in 487 patients from the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy study (OR=2.6, P=0.003). In 25 University of Illinois sickle cell disease patients, concentrations of urine kidney injury molecule-1 correlated with urine cell-free hemoglobin concentrations (r=0.59, P=0.002). Exposing human proximal tubular cells to increasing cell-free hemoglobin led to increasing concentrations of supernatant kidney injury molecule-1 (P=0.01), reduced viability (P=0.01) and induction of HMOX1 and SOD2. HMOX1 rs743811 associated with chronic kidney disease stage (OR=3.0, P=0.0001) in the University of Illinois cohort and end-stage renal disease (OR=10.0, P=0.0003) in the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy cohort. Longer HMOX1 GT-tandem repeats (>25) were associated with lower estimated glomerular filtration rate in the University of Illinois cohort (P=0.01). Our findings point to an association of APOL1 G1/G2 with kidney disease in sickle cell disease, possibly through increased risk of hemoglobinuria, and associations of HMOX1 variants with kidney disease, possibly through reduced protection of the kidney from hemoglobin-mediated toxicity.
Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through association with haptoglobin-related protein. APOL1 G1/G2 variants are the strongest genetic predictors of kidney disease in the general African-American population. A single report associated APOL1 G1/G2 with sickle cell nephropathy. In 221 patients with sickle cell disease at the University of Illinois at Chicago, we replicated the finding of an association of APOL1 G1/G2 with proteinuria, specifically with urine albumin concentration (β=1.1, P =0.003), observed an even stronger association with hemoglobinuria (OR=2.5, P =4.3×10 −6 ), and also replicated the finding of an association with hemoglobinuria in 487 patients from the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy study (OR=2.6, P =0.003). In 25 University of Illinois sickle cell disease patients, concentrations of urine kidney injury molecule-1 correlated with urine cell-free hemoglobin concentrations (r=0.59, P =0.002). Exposing human proximal tubular cells to increasing cell-free hemoglobin led to increasing concentrations of supernatant kidney injury molecule-1 ( P =0.01), reduced viability ( P =0.01) and induction of HMOX1 and SOD2 . HMOX1 rs743811 associated with chronic kidney disease stage (OR=3.0, P =0.0001) in the University of Illinois cohort and end-stage renal disease (OR=10.0, P =0.0003) in the Walk-Treatment of Pulmonary Hypertension and Sickle cell Disease with Sildenafil Therapy cohort. Longer HMOX1 GT-tandem repeats (>25) were associated with lower estimated glomerular filtration rate in the University of Illinois cohort ( P =0.01). Our findings point to an association of APOL1 G1/G2 with kidney disease in sickle cell disease, possibly through increased risk of hemoglobinuria, and associations of HMOX1 variants with kidney disease, possibly through reduced protection of the kidney from hemoglobin-mediated toxicity.
Author Shah, B.
Kanias, T.
Kittles, R.
Saraf, S. L.
Gladwin, M. T.
Arruda, J. A. L.
Singh, A. K.
Machado, R. F.
Zhang, X.
Gudehithlu, K. P.
Gordeuk, V. R.
AuthorAffiliation 3 Division of Nephrology, Department of Medicine, John H. Stroger, Jr Hospital of Cook County, Chicago, IL
6 Division of Nephrology, Department of Medicine, University of Illinois at Chicago, IL, USA
1 Division of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, IL
2 Division of Pulmonary, Allergy, and Critical Care Medicine, Vascular Medicine Institute, University of Pittsburgh, PA
4 Department of Surgery, University of Arizona, Tucson, AZ
5 Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Illinois at Chicago, IL
AuthorAffiliation_xml – name: 6 Division of Nephrology, Department of Medicine, University of Illinois at Chicago, IL, USA
– name: 1 Division of Hematology & Oncology, Department of Medicine, Comprehensive Sickle Cell Center, University of Illinois at Chicago, IL
– name: 5 Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Illinois at Chicago, IL
– name: 4 Department of Surgery, University of Arizona, Tucson, AZ
– name: 3 Division of Nephrology, Department of Medicine, John H. Stroger, Jr Hospital of Cook County, Chicago, IL
– name: 2 Division of Pulmonary, Allergy, and Critical Care Medicine, Vascular Medicine Institute, University of Pittsburgh, PA
Author_xml – sequence: 1
  givenname: S. L.
  surname: Saraf
  fullname: Saraf, S. L.
– sequence: 2
  givenname: X.
  surname: Zhang
  fullname: Zhang, X.
– sequence: 3
  givenname: B.
  surname: Shah
  fullname: Shah, B.
– sequence: 4
  givenname: T.
  surname: Kanias
  fullname: Kanias, T.
– sequence: 5
  givenname: K. P.
  surname: Gudehithlu
  fullname: Gudehithlu, K. P.
– sequence: 6
  givenname: R.
  surname: Kittles
  fullname: Kittles, R.
– sequence: 7
  givenname: R. F.
  surname: Machado
  fullname: Machado, R. F.
– sequence: 8
  givenname: J. A. L.
  surname: Arruda
  fullname: Arruda, J. A. L.
– sequence: 9
  givenname: M. T.
  surname: Gladwin
  fullname: Gladwin, M. T.
– sequence: 10
  givenname: A. K.
  surname: Singh
  fullname: Singh, A. K.
– sequence: 11
  givenname: V. R.
  surname: Gordeuk
  fullname: Gordeuk, V. R.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26206798$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS3Uik4Lb4BQlmwy2I7ta7NAQhWUSpW6KWvLf5m4JPZgZyr17cl0OoiyYGXZ95zv6Pqco5OUU0DoHcHrrqPs42DCZOY8rikmfE0ok8BfoRXhirYSKDlBK9wp3AoM8gyd13qPMcVKwWt0RgXFApRcodurkMIcXfNgSjRpro1JvnFhHNu-hNAMYcqbMduYmm3JLtQa06ZZbjW6n2N4UjYpbIeSt2YeHt-g096MNbx9Pi_Qj29f7y6_tze3V9eXX25axxmeWyEsYCEJGMDAQBLhqQAA6yx3XHAavHeeWkqtsdIRpgI2HfYgfc-ktd0Fuj5wfTb3elviZMqjzibqp4dcNtqUZa8xaG6VZ0YyxRcvLGsLy5XqGDgOPXC_sD4fWNudnYJ3Ic3FjC-gLycpDnqTHzTjigBXC-DDM6DkX7tQZz3Fuv8Zk0LeVU2ASIWFEmSRvv8760_IsZFF8OkgcCXXWkKvXZzNHPM-Oo6aYL2vXx_r1_v69aH-xcz-MR_5_7X9BsKet1o
CitedBy_id crossref_primary_10_1111_bjh_17647
crossref_primary_10_1111_bjh_17606
crossref_primary_10_1007_s12288_018_1018_x
crossref_primary_10_3390_ijms25105427
crossref_primary_10_1080_17474086_2017_1395279
crossref_primary_10_2217_pgs_2016_0007
crossref_primary_10_3390_ijms20010117
crossref_primary_10_3390_ijms26062817
crossref_primary_10_1186_s13045_022_01237_z
crossref_primary_10_1039_D3AN00345K
crossref_primary_10_1002_prca_201500133
crossref_primary_10_1089_ars_2016_6659
crossref_primary_10_1111_bjh_14842
crossref_primary_10_1111_trf_14407
crossref_primary_10_1111_bjh_14724
crossref_primary_10_1371_journal_pone_0162652
crossref_primary_10_1016_j_htct_2020_01_009
crossref_primary_10_1111_bjh_17832
crossref_primary_10_1016_j_blre_2022_100983
crossref_primary_10_1016_j_hoc_2022_06_006
crossref_primary_10_1111_bjh_14280
crossref_primary_10_2217_bmm_2019_0105
crossref_primary_10_1016_j_ebiom_2017_09_001
crossref_primary_10_1016_j_trsl_2018_01_007
crossref_primary_10_1371_journal_pone_0164364
crossref_primary_10_3389_fgene_2021_595702
crossref_primary_10_1007_s00467_021_05126_4
crossref_primary_10_1177_1535370216636726
crossref_primary_10_1097_MOH_0000000000000241
crossref_primary_10_1111_apa_17025
crossref_primary_10_1152_ajprenal_00233_2019
crossref_primary_10_1155_2017_1480514
crossref_primary_10_3390_ijms22158174
crossref_primary_10_1038_s41581_022_00540_9
crossref_primary_10_1111_bjh_19603
crossref_primary_10_1242_dmm_049765
crossref_primary_10_1111_bjh_17224
crossref_primary_10_1182_bloodadvances_2017005231
crossref_primary_10_1186_s43054_024_00283_1
crossref_primary_10_1182_blood_2018_05_853929
crossref_primary_10_1001_jamanetworkopen_2023_37484
crossref_primary_10_1089_omi_2016_0125
crossref_primary_10_1182_asheducation_2017_1_435
crossref_primary_10_1182_bloodadvances_2019000883
crossref_primary_10_1053_j_ajkd_2020_01_006
crossref_primary_10_1053_j_ajkd_2023_12_014
crossref_primary_10_1182_bloodadvances_2022007451
crossref_primary_10_1016_j_freeradbiomed_2019_07_004
crossref_primary_10_1097_HS9_0000000000000762
crossref_primary_10_23876_j_krcp_20_091
crossref_primary_10_1002_ajh_25763
crossref_primary_10_1111_trf_14788
crossref_primary_10_1016_j_bcmd_2022_102699
crossref_primary_10_1016_j_hemonc_2020_09_003
crossref_primary_10_1182_bloodadvances_2022007809
crossref_primary_10_1182_bloodadvances_2018028878
crossref_primary_10_1053_j_ajkd_2018_12_027
ContentType Journal Article
Copyright Copyright© Ferrata Storti Foundation.
Copyright© Ferrata Storti Foundation 2015
Copyright_xml – notice: Copyright© Ferrata Storti Foundation.
– notice: Copyright© Ferrata Storti Foundation 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3324/haematol.2015.124875
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1592-8721
EndPage 1284
ExternalDocumentID oai_doaj_org_article_5b9d4a8495df476796b599347c57f75d
PMC4591759
26206798
10_3324_haematol_2015_124875
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: R01 HL098032
– fundername: NHLBI NIH HHS
  grantid: R01HL096973
– fundername: NHLBI NIH HHS
  grantid: K23 HL098454
– fundername: NHLBI NIH HHS
  grantid: P01HL103455
– fundername: NHLBI NIH HHS
  grantid: R01 HL111656
– fundername: NHLBI NIH HHS
  grantid: R01 HL096973
– fundername: NHLBI NIH HHS
  grantid: R01HL098032
– fundername: NCATS NIH HHS
  grantid: KL2TR000048
– fundername: NHLBI NIH HHS
  grantid: K23HL098454
– fundername: NHLBI NIH HHS
  grantid: P01 HL103455
GroupedDBID ---
29I
2WC
53G
5GY
5RE
5VS
AAFWJ
AAYXX
ADBBV
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BTFSW
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GROUPED_DOAJ
H13
HYE
KQ8
OK1
OVT
P2P
RHI
RNS
RPM
SJN
TFS
TR2
W8F
WOQ
WOW
C1A
CGR
CUY
CVF
ECM
EIF
M~E
NPM
RHF
SV3
UDS
7X8
5PM
ID FETCH-LOGICAL-c540t-66b706817a70747816d26777bcb5c5652eddcd2b22bab8c149e0a30d78df48bb3
IEDL.DBID DOA
ISSN 0390-6078
IngestDate Wed Aug 27 01:26:39 EDT 2025
Thu Aug 21 18:01:01 EDT 2025
Thu Jul 10 23:23:14 EDT 2025
Thu Jan 02 23:03:15 EST 2025
Thu Apr 24 23:02:02 EDT 2025
Tue Jul 01 04:22:00 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License Copyright© Ferrata Storti Foundation.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-66b706817a70747816d26777bcb5c5652eddcd2b22bab8c149e0a30d78df48bb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/5b9d4a8495df476796b599347c57f75d
PMID 26206798
PQID 1718906961
PQPubID 23479
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_5b9d4a8495df476796b599347c57f75d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4591759
proquest_miscellaneous_1718906961
pubmed_primary_26206798
crossref_citationtrail_10_3324_haematol_2015_124875
crossref_primary_10_3324_haematol_2015_124875
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-10-01
PublicationDateYYYYMMDD 2015-10-01
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-01
  day: 01
PublicationDecade 2010
PublicationPlace Italy
PublicationPlace_xml – name: Italy
PublicationTitle Haematologica (Roma)
PublicationTitleAlternate Haematologica
PublicationYear 2015
Publisher Ferrata Storti Foundation
Publisher_xml – name: Ferrata Storti Foundation
SSID ssj0020997
Score 2.4006596
Snippet Intravascular hemolysis and hemoglobinuria are associated with sickle cell nephropathy. ApoL1 is involved in cell-free hemoglobin scavenging through...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1275
SubjectTerms Adult
Anemia, Sickle Cell - complications
Anemia, Sickle Cell - genetics
Apolipoprotein L1
Apolipoproteins - genetics
Cell Line
Cohort Studies
Female
Gene Expression
Genetic Predisposition to Disease
Genetic Variation
Genotype
Heme Oxygenase-1 - genetics
Heme Oxygenase-1 - metabolism
Hemoglobins - genetics
Hemoglobins - metabolism
Hemoglobinuria
Hepatitis A Virus Cellular Receptor 1
Humans
Kidney Diseases - etiology
Kidney Diseases - metabolism
Kidney Tubules, Proximal - metabolism
Lipoproteins, HDL - genetics
Male
Membrane Glycoproteins - genetics
Membrane Glycoproteins - urine
Middle Aged
Receptors, Virus - genetics
Title Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy
URI https://www.ncbi.nlm.nih.gov/pubmed/26206798
https://www.proquest.com/docview/1718906961
https://pubmed.ncbi.nlm.nih.gov/PMC4591759
https://doaj.org/article/5b9d4a8495df476796b599347c57f75d
Volume 100
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_Sg3gRbf1YqyWCeIvdj3weq1iK0PZiobeQr-UV27xHfS30v3cm2fd4T4RePO5uQsJMsvObyeQ3hHwSSfdm1IHF1o2MmySYlp1kKTkj-OCEK9UbTs_kyQX_cSkuN0p9YU5YpQeugjsU3kTuNOD4OHKFUQ8vwKZyFYQalYj49wWbt3KmJlcL74OW8wMDzhFYwXppbgD0cDhzSIY6x2OHTnwB81ZyDDeMUuHu_xfg_DtvcsMQHb8gzycESY_qzF-SJynvkr2jDKPdPNDPtOR0lmD5Lnl6Oh2d75FzJJiGLvQevGNMfqEuR4pxezbepkRn6WaO7CBXmS7q5QEwahSeQI2_rlNpSXNaYFkFQI0Pr8jF8fef307YVE2BBUBlSyalV63UnXKqkOZ3MvZSKeWDFwFgXZ9iDLH3fe-d1wE8p9S6oY1Kg-C198NrspPnOb0l1PWhDUY4HYLnZkiaj4MPAIwSgIdRqoYMK3HaMFGNY8WLawsuByrBrpRgUQm2KqEhbN1rUak2Hmn_FTW1botE2eUFLB87LR_72PJpyMeVni1sLJSly2l-99t2YLVNK43sGvKm6n09FLL44_FVQ9TWitiay_aXfDUr5N1cgIMszLv_Mfl98gzlUXML35Od5e1d-gAYaekPynY4KMGrP-SkD4M
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+variants+and+cell-free+hemoglobin+processing+in+sickle+cell+nephropathy&rft.jtitle=Haematologica+%28Roma%29&rft.au=Santosh+L.+Saraf&rft.au=Xu+Zhang&rft.au=Binal+Shah&rft.au=Tamir+Kanias&rft.date=2015-10-01&rft.pub=Ferrata+Storti+Foundation&rft.issn=0390-6078&rft.eissn=1592-8721&rft.volume=100&rft.issue=10&rft_id=info:doi/10.3324%2Fhaematol.2015.124875&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5b9d4a8495df476796b599347c57f75d
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon